Geiger Counter Ltd : Net Asset Value(s) GEIGER COUNTER

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Geiger Counter Ltd : Net Asset Value(s)
GEIGER COUNTER LIMITED   
         
Date of Announcement: 06/10/2016      
         
Net Asset Values per share as at:05/10/2016     
         
The unaudited net asset value (NAV) of the company is noted below in pence per share. 
         
        Pence per share
Geiger Counter Limited    20.83 
         
         




Net asset value as at 05.10.2016 of
Geiger Counter Ltd ordinary no par value shares
(TIDM: GCL):
NAV-bid........... : 20.83 GBp



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investigation of Stock Transactions: TASK, VBTX, TURN Insights

Updated Category News Views 125

Financial Investigations for Shareholders of TASK, VBTX, and TURN Halper Sadeh LLC is actively investigating several companies regarding potential violations of federal securities laws affecting shareholders. The investigations focus on significant transactions involving TaskUs, Veritex Holdings, and 180 Degree Capital Corp. TaskUs, Inc. and Its Acquisition by Blackstone...

Continue Reading
Comprehensive Analysis of NVIDIA in the Semiconductor Market

Updated Category News Views 678

Understanding NVIDIA's Position in the Semiconductor Sector In today's fast-paced business environment, it is crucial for investors and industry followers to conduct in-depth analyses of key companies. This article offers a detailed comparison of NVIDIA (NASDAQ: NVDA) with its main competitors in the Semiconductors & Semiconductor Equipment sector. By looking at important...

Continue Reading
Invivyd Set to Showcase PEMGARDA™ Findings at Upcoming Event

Updated Category News Views 54

Invivyd Prepares for IDWeek 2024 Presentations Invivyd, Inc. (NASDAQ: IVVD) is an innovative biopharmaceutical company focusing on creating solutions for serious viral infections. As they gear up for their participation in IDWeek 2024, they will be unveiling exciting new data concerning their investigational monoclonal antibody, PEMGARDA™ (pemivibart). The conference is...

Continue Reading
The Rising Stars: Growth Potential of Key Investments

Updated Category News Views 95

Carnival made waves post-pandemic as it clawed its way back from meme stock purgatory. Traders watched the cruise line stumble but now see flickers of recovery amidst hefty debt burdens that peaked around $35 billion. Sure, they pulled in a whopping $1.7 billion net income in the last quarter, but those profit forecasts? All over the place—talk about a mixed bag. And...

Continue Reading
PharmAla Partners with Logistics Expert for Clinical Trials

Updated Category News Views 114

PharmAla Forms Strategic Alliance for Enhanced US Distribution PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a dedicated biotechnology company, is excited to share its latest strategic move aimed at improving service delivery in the United States. The company has engaged a trusted third-party logistics partner, specialized...

Continue Reading